XML 51 R41.htm IDEA: XBRL DOCUMENT
v3.25.3

Significant Agreements - Roche License Agreement (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
May 05, 2021 | Jun. 30, 2017 | May 31, 2014 | Feb. 28, 2014 | Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Dec. 31, 2024
License Agreement [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | $ 2,415 | $ 970 | $ 9,663 | $ 133,034 |
Collaborative Arrangement |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |
Portion of revenue and expenses attributable to company, Percentage |  |  |  |  |  |  | 30.00% |  |
Roche |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |
Revenue, Remaining performance obligation, Amount |  |  |  |  | 0 |  | $ 0 |  | $ 0
Roche | Collaborative Arrangement |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |
Upfront payment pursuant to license agreement |  |  |  | $ 30,000 |  |  |  |  |
Milestone payment received, Clinical milestone |  |  | $ 15,000 |  |  |  |  |  |
Milestone achievement, Clinical milestone | $ 60,000 | $ 30,000 |  |  |  |  |  |  |
Potential payment upon achievement of development, regulatory and various first commercial sales milestones |  |  |  |  |  |  | 290,000 |  |
Potential payment for achievement of non U.S. commercial sales milestones |  |  |  |  |  |  | $ 175,000 |  |
License agreement, Cost allocation, Percentage |  |  |  |  |  |  | 100.00% |  |
Portion of revenue and expenses attributable to company, Percentage |  |  |  |  |  |  | 70.00% |  |
Potential Payment for US Commercial Sales Milestones |  |  |  |  |  |  | $ 155,000 |  |
Collaboration revenue |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | $ 2,415 | $ 970 | $ 9,613 | $ 132,984 |

X
- Definition Collaboration Revenue, License, Upfront Payment + References No definition available. + Details
Name: | prta_CollaborationRevenueLicenseUpfrontPayment
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition [Line Items] for License Agreement [Table] + References No definition available. + Details
Name: | prta_LicenseAgreementLineItems
Namespace Prefix: | prta_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Potential Alternative Commercial Sales Milestones + References No definition available. + Details
Name: | prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Potential Payment Upon Achievement of Development, Regulatory and Various First Commercial Sales Milestones + References No definition available. + Details
Name: | prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Potential Payment for Achievement of non U.S. Commercial Sales Milestones + References No definition available. + Details
Name: | prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Licensing Agreement, Cost Allocation, Percentage + References No definition available. + Details
Name: | prta_LicensingAgreementCostAllocationPercentage
Namespace Prefix: | prta_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Licensing Agreement, Portion of Revenue and Expenses Attributable to Company, Percentage + References No definition available. + Details
Name: | prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage
Namespace Prefix: | prta_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Achievement, Clinical Milestone -recognized where milestone was achieved at the end of the period presented. + References No definition available. + Details
Name: | prta_MilestoneAchievementClinicalMilestone
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone Payment Received, Clinical Milestone + References No definition available. + Details
Name: | prta_MilestonePaymentReceivedClinicalMilestone
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=prta_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=prta_CollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |